A panel of expert oncologists reviews key updates from recent meetings regarding the testing and treatment of metastatic colorectal cancer in the context of real-world clinical practice.
EP. 1: Molecular Testing in Metastatic CRCNovember 30th 2022
Opening their discussion on metastatic colorectal cancer management, expert panelists reflect on the molecular testing paradigm in the setting of diagnosis and workup.
EP. 2: Role of ctDNA and MRD in Identifying and Managing Metastatic CRCNovember 30th 2022
Shared insight on the optimal use of circulating tumor DNA and minimal residual disease in the identification and management of metastatic colorectal cancer.
EP. 3: PARADIGM Trial: Panitumumab in RAS Wild-Type and Left-Sided Metastatic CRCDecember 7th 2022
Expert perspectives on the PARADIGM study, which highlighted the role of panitumumab in combination with frontline chemotherapy in patients with left-sided, RAS wild-type metastatic colorectal cancer.
EP. 4: Overview of HER2-Positive Metastatic CRCDecember 7th 2022
A panel of expert oncologists consider how HER2 expression can positively impact the selection of targeted therapies for patients with metastatic colorectal cancer.
EP. 5: DESTINY-CRC01: Role of Trastuzumab Deruxtecan in HER2-Positive Metastatic CRCDecember 14th 2022
Shared perspective on the use of trastuzumab deruxtecan in HER2+ metastatic colorectal cancer following results from the DESTINY-CRC01 trial.
EP. 6: MOUNTAINEER Study: Tucatinib in Patients With HER2-Positive Metastatic CRCDecember 14th 2022
Expert panelists review data from the MOUNTAINEER study, which tested tucatinib alone or in combination with trastuzumab in patients with metastatic colorectal cancer.
EP. 8: Emerging Targets in the Treatment of Metastatic Colorectal CancerDecember 21st 2022
A panel of expert oncologists discusses advances in the treatment of BRAFV600E metastatic colorectal cancer and also reviews novel targets being investigated in the setting of metastatic colorectal cancer.
EP. 9: Updates in the Management of KRASG12C-Mutated Metastatic CRCDecember 28th 2022
Centering discussion on KRASG12C-mutated metastatic colorectal cancer, panelists highlight recent clinical studies of targeted agents in this subset of disease.
EP. 10: Role of Immunotherapies in Microsatellite Stable Metastatic CRCDecember 28th 2022
Shared insight on the potential role for immunotherapeutic agents in the setting of microsatellite stable metastatic colorectal cancer.
EP. 11: FRESCO-2 Trial: Role of Fruquitinib in Refractory Metastatic CRCJanuary 4th 2023
Focused discussion on the FRESCO-2 trial, which analyzed use of fruquitinib in the refractory setting of metastatic colorectal cancer.
EP. 12: Metastatic CRC: Unmet Needs and Future Directions in CareJanuary 4th 2023
Closing out their review of the metastatic colorectal cancer treatment paradigm, expert panelists consider how the treatment armamentarium will continue to evolve.